Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0027121 (
myositis
)
4,538
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A disintegrin and metalloproteinases (ADAMs) are believed to be involved in the pathogenesis of many fibrosis-related diseases. However, little is known regarding the significance of
ADAM17
as a biomarker for interstitial lung disease (ILD). In this study, by using the RT-PCR, western blotting and ELISA, we detected the expression level of
ADAM17
in peripheral blood mononuclear cells and serum from idiopathic pulmonary fibrosis (IPF) patients, connective tissue disease associated ILD (CTD-ILD) patients and healthy controls, and correlations between clinical and laboratory parameters were also analyzed. We found that IPF patients and CTD-ILD patients showed higher levels of
ADAM17
than healthy controls. Moreover,
ADAM17
in IPF patients with acute exacerbation (AE-IPF) was significantly higher than that in stable IPF (S-IPF) patients. Expression of
ADAM17
was positively correlated with disease duration and CRP but negatively correlated with diffusing capacity of carbon monoxide (D
L
CO) and total lung capacity (TLC). Among the CTD-ILD patients, SSc-ILD patients had the highest serum levels of
ADAM17
compared with the RA-ILD, SS-ILD and
IIM
-ILD groups and
ADAM17
expression levels were correlated with image grading. In conclusion, this study showed that
ADAM17
is highly expressed in ILD patients and is associated with disease activity and severity. Additionally,
ADAM17
expression is not only related to the primary CTDs, but also to image grading.
ADAM17
may serve as a new biomarker for ILD.
...
PMID:Association of ADAM17 Expression Levels in Patients with Interstitial Lung Disease. 3146 50
